The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Consulting or Advisory Role - AstraZeneca; Merck
Travel, Accommodations, Expenses - AstraZeneca; Merck
Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.
 
Salma K. Jabbour
Consulting or Advisory Role - Merck Sharp & Dohme
Research Funding - Merck Sharp & Dohme (Inst); Nestle health science (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Ki Hyeong Lee
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD
 
Nicolaj Frost
Honoraria - AstraZeneca; AstraZeneca; Berlin-Chemie; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; Roche Pharma AG
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Takeda
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Bristol-Myers Squibb; Lilly
(OPTIONAL) Uncompensated Relationships - Deutsche Forschungsgemeinschaft
 
Dariusz Kowalski
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Serono; MSD; Roche/Genentech
 
Valeriy Vladimirovich Breder
Honoraria - Bayer; BioCad; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - Bayer; BioCad; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Ipsen; Roche; Takeda
 
Theodore Pollock
Research Funding - Merck (Inst)
 
Noemi Reguart
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; MSD; Roche; Roche Molecular Diagnostics
Research Funding - Novartis; Pfizer
Travel, Accommodations, Expenses - MSD; Roche
 
Baerin Houghton
No Relationships to Disclose
 
Xavier Quantin
Honoraria - Bristol-Myers Squibb; Roche/Genentech
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer
 
Steven M. Keller
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Hong Liu
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Bilal Piperdi
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Martin Reck
No Relationships to Disclose